🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Empagliflozin on Inflammation

RecruitingPhase 4Ages 18 Years - anyAllHotel Dieu de France Hospital
NCT07292909 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood. He hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect. To document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure. Patients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measure

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery Exclusion Criteria: * • Patients who have been taking an SGLT-2 inhibitor during the last month * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID… * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy * Patients with an acute coronary syndrome within the last month * Intervention on a restenotic lesion or lesion in a saphenous vein graft * Creatinine clearance less than 30 mL/min * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)
💊

What it tests

  • Empagliflozin (SGLT2i)
  • Placebo
📍

Where

1 site
Hotel Dieu de France
Beirut, Lebanon
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy